Citations

Clear

3042 citation(s) found for "Kumar, S".

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
Kumar, Shaji , LaPlant, Betsy, Zonder, Jeffrey A. , Fruth, Briant, Erlichman, Charles , Stewart, A. Keith, Kumar, Shaji K , Chng, Wee Joo , Callander, Natalie S. , Fonseca, Rafaël , Roy, Vivek

Mayo Clinic

Blood | November 14, 2014 | Volume: 125 | Issue: 3 | Pages: 443-448

10.1182/blood-2014-05-573741 | PMID 25395429 Get It

Key Points Dinaciclib is a novel cdk inhibitor that demonstrates single agent activity in myeloma. Dinaciclib has a safety profile that is easily manageable.
Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis
Kaufman, Gregory P., Dispenzieri, Angela , Lacy, Martha Q. , Hayman, Suzanne R. , Leung, Nelson , Dingli, David , Lust, John A., Lin, Yi , Kapoor, Prashant , Zeldenrust, Steven R., Kyle, Robert A. , Kumar, Shaji , Gertz, Morie A. , Buadi, Francis K. , Go, Ronald S. , Rajkumar, S. Vincent , Leung, Nelson , Dispenzieri, Angela , Dingli, David , Lin, Yi

Mayo Clinic

American Journal of Hematology | November 12, 2014 | Volume: 90 | Issue: 3 | Pages: 181-186

10.1002/ajh.23898 | PMID 25388651 Get It

Despite successful treatment of the clonal plasma cell implicated in its pathogenesis, patients with AL amyloidosis (AL) experience significant morbidity related to underlying amyloid mediated organ dysfunction. While normalization of the serum free light chain measurements [normal ratio of involved and uninvolved free light chains (nFLCr)] is the goal of therapy and centerpiece of hematologic response criteria, achieving (or not achieving) meaningful organ response (OR) is clinically significant for its implications on long‐term symptomatology as well as overall survival (OS), and remains the ultimate goal of treatment. Expectations for organ recovery following successful therapy leading to nFLCr in AL remain poorly described. We evaluated the timeframe and predictive factors for OR, and long‐term outcome, in 313 AL patients who achieved nFLCr following therapy initiation. OR was seen in 80% of surviving AL patients within 1‐year of nFLCr. Patients achieving early OR within 1 year of nFLCr had superior OS compared with those who despite obtaining nFLCr did not achieve early OR. We further evaluated factors predicting OR and OS among patients achieving nFLCr. Higher values of dFLC (involved–uninvolved) at diagnosis predict OR, and early OR predicts improved OS following successful hematologic therapy in AL. Am. J. Hematol. 90:181–186, 2015. © 2014 Wiley Periodicals, Inc.
Clinical course and prognosis of non‐secretory multiple myeloma
Kumar, Shaji , Dispenzieri, Angela , Greenberg, Alexandra J. , Kyle, Robert A. , Lacy, Martha Q. , Chawla, Sagar S, Larson, Dirk R. , Chawla, Sagar , Gertz, Morie A. , Rajkumar, S. Vincent , Dispenzieri, Angela

Mayo Clinic

European Journal of Haematology | November 10, 2014 | Volume: 95 | Issue: 1 | Pages: 57-64

10.1111/ejh.12478 | PMID 25382589 Get It

Abstract Objective To determine the prognosis of patients with non‐secretory myeloma. Methods We studied 124 patients diagnosed with multiple myeloma who had no monoclonal protein detected on serum and urine immunofixation at diagnosis and on all subsequent follow‐up testing (non‐secretory myeloma). The overall survival ( OS ) of patients with non‐secretory myeloma was compared with 6953 patients with typical myeloma seen during the same time period in whom a monoclonal protein was detected at the time of diagnosis. Results One hundred and twenty‐four patients met criteria for non‐secretory multiple myeloma. The median follow‐up was 102 months (range, 1–204 months). The median progression‐free survival with initial therapy was 28.6 months, and the median OS was 49.3 months. There was a significant improvement in OS since 2001; median survival 43.8 months (prior to 2001) vs. 99.2 months (2001–2012), P < 0.001. OS was superior in patients with a normal baseline FLC ratio ( n = 10) compared to patients with an abnormal ratio ( n = 19), medians not reached in both groups. Prior to 2001, OS was similar in non‐secretory myeloma ( n = 86) and secretory myeloma ( n = 4011), median 3.6 vs. 3.5 yr, respectively, P = 0.63. However, among patients diagnosed between 2001 and 2012, OS was superior in non‐secretory myeloma ( n = 36) compared to secretory myeloma ( n = 2942), median 8.3 vs. 5.4 yr, respectively, P = 0.03. Conclusions Non‐secretory myeloma is an uncommon subtype of multiple myeloma. In the last decade, there has been an improvement in the survival of non‐secretory myeloma and appears superior to secretory myeloma.
Pathogenic Ischemic Stroke Phenotypes in the NINDS-Stroke Genetics Network
Ay, Hakan , Arsava, Ethem Murat , Andsberg, Gunnar , Benner, Thomas, Brown, Robert D. , Chapman, Sherita , Delavaran, Hossein , Dichgans, Martin , Engström, Gunnar , Giralt‐Steinhauer, Eva , Grewal, Raji P., Gwinn, Katrina , Jiménez-Conde, Jordi , Katsnelson, Michael , Kissela, Brett , Kittner, Steven J. , Kleindorfer, Dawn , Labovitz, Daniel , Lanfranconi, Silvia , Lee, Jin‐Moo , Lehm, Manuel, Lemmens, Robin , Levi, Christopher , Li, Linxin , Lindgren, Arne, Markus, Hugh S. , McArdle, Patrick F. , Melander, Olle , Peddareddygari, Leema Reddy , Pedersén, Annie , Pera, Joanna , Rannikmäe, Kristiina , Rexrode, Kathryn M. , Rich, Stephen S. , Rothwell, Peter M. , Schmidt, Reinhold , Schürks, Markus , Seiler, Stephan , Słowik, Agnieszka , Sudlow, Cathie , Thijs, Vincent , Woodfield, Rebecca, Worrall, Bradford B. , Chapman, Sherita N, Cole, John W. , Giralt-Steinhauer, Eva, Jern, Christina, Jood, Katarina, Kleindorfer, Dawn O, Labovitz, Daniel L, Levi, Chris, Rhodes, David, Rundek, Tatjana , Slowik, Agnieszka, Jern, Christina , Jood, Katarina , Lindgren, Arne, Norrving, Bo , Rhodes, David , Roquer, Jaume , Rosand, Jonathan M. , Sacco, Ralph L. , Sharma, Pankaj Kumar , Meschia, James F. , Dichgans, Martin , Rich, Stephen S , Lemmens, Robin , Lee, Jin-Moo

Mayo Clinic

Stroke | November 7, 2014 | Volume: 45 | Issue: 12 | Pages: 3589-3596

10.1161/strokeaha.114.007362 | PMID 25378430 Get It

Background and Purpose— NINDS (National Institute of Neurological Disorders and Stroke)-SiGN (Stroke Genetics Network) is an international consortium of ischemic stroke studies that aims to generate high-quality phenotype data to identify the genetic basis of pathogenic stroke subtypes. This analysis characterizes the etiopathogenetic basis of ischemic stroke and reliability of stroke classification in the consortium. Methods— Fifty-two trained and certified adjudicators determined both phenotypic (abnormal test findings categorized in major pathogenic groups without weighting toward the most likely cause) and causative ischemic stroke subtypes in 16 954 subjects with imaging-confirmed ischemic stroke from 12 US studies and 11 studies from 8 European countries using the web-based Causative Classification of Stroke System. Classification reliability was assessed with blinded readjudication of 1509 randomly selected cases. Results— The distribution of pathogenic categories varied by study, age, sex, and race ( P <0.001 for each). Overall, only 40% to 54% of cases with a given major ischemic stroke pathogenesis (phenotypic subtype) were classified into the same final causative category with high confidence. There was good agreement for both causative (κ 0.72; 95% confidence interval, 0.69–0.75) and phenotypic classifications (κ 0.73; 95% confidence interval, 0.70–0.75). Conclusions— This study demonstrates that pathogenic subtypes can be determined with good reliability in studies that include investigators with different expertise and background, institutions with different stroke evaluation protocols and geographic location, and patient populations with different epidemiological characteristics. The discordance between phenotypic and causative stroke subtypes highlights the fact that the presence of an abnormality in a patient with stroke does not necessarily mean that it is the cause of stroke.
IgG4‐related (neurologic) disease: diagnostic challenges, clinical clues and expanding spectrum
Flanagan, Eoin P. , Chowdhary, Vaidehi , McCarthy, James T. , Smyrk, Thomas C. , Chari, Suresh T. , Kumar, Neeraj , Chowdhary, Vaidehi R, Flanagan, E P , Chari, Suresh T

Mayo Clinic

International Journal of Rheumatic Diseases | October 10, 2014 | Volume: 18 | Issue: 7 | Pages: 807-809

10.1111/1756-185x.12465 | PMID 25307728 Get It

Non-metastatic 2 (NME2)-mediated suppression of lung cancer metastasis involves transcriptional regulation of key cell adhesion factor vinculin
Thakur, Ram Krishna, Yadav, Vinod Kumar , Kumar, Akinchan, Singh, Ankita, Pal, Krishnendu , Hoeppner, Luke H. , Saha, Dhurjhoti , Purohit, Gunjan , Basundra, Richa, Kar, Anirban, Halder, Rashi , Kumar, Pankaj, Baral, Aradhita, Kumar, MJ Mahesh, Baldi, Alfonso , Banerjee‬‬‬‬‬‬‬‬‬, Rintu , Kumar, Praveen , Shridhar, Viji , Chowdhury, Shantanu , Hoeppner, Luke, Kumar, Pankaj, Vincenzi, Bruno , Lorenzon, Laura , Mukhopadhyay, Debabrata , Pal, Krishnendu , Banerjee, Rajkumar

Mayo Clinic

Nucleic Acids Research | September 23, 2014 | Volume: 42 | Issue: 18 | Pages: 11589-11600

10.1093/nar/gku860 | PMID 25249619 Get It

Abstract Tumor metastasis refers to spread of a tumor from site of its origin to distant organs and causes majority of cancer deaths. Although &gt;30 metastasis suppressor genes (MSGs) that negatively regulate metastasis have been identified so far, two issues are poorly understood: first, which MSGs oppose metastasis in a tumor type, and second, which molecular function of MSG controls metastasis. Herein, integrative analyses of tumor-transcriptomes (n = 382), survival data (n = 530) and lymph node metastases (n = 100) in lung cancer patients identified non-metastatic 2 (NME2) as a key MSG from a pool of &gt;30 metastasis suppressors. Subsequently, we generated a promoter-wide binding map for NME2 using chromatin immunoprecipitation with promoter microarrays (ChIP-chip), and transcriptome profiling. We discovered novel targets of NME2 which are involved in focal adhesion signaling. Importantly, we detected binding of NME2 in promoter of focal adhesion factor, vinculin. Reduced expression of NME2 led to enhanced transcription of vinculin. In comparison, NME1, a close homolog of NME2, did not bind to vinculin promoter nor regulate its expression. In line, enhanced metastasis of NME2-depleted lung cancer cells was found in zebrafish and nude mice tumor models. The metastatic potential of NME2-depleted cells was remarkably diminished upon selective RNA-i-mediated silencing of vinculin. Together, we demonstrate that reduced NME2 levels lead to transcriptional de-repression of vinculin and regulate lung cancer metastasis.
The IRF5–TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share
Kottyan, Leah C. , Zoller, Erin E., Bene, Jessica, Lu, Xiaoming , Kelly, Jennifer A. , Rupert, Andrew, Lessard, Christopher J. , Vaughn, Samuel , Marion, Miranda C. , Namjou, Bahram , Adler, Adam, Rasmussen, Astrid , Glenn, Stuart B., Montgomery, Courtney G. , Hirschfield, Gideon M. , Coltescu, Catalina, Amos, Chris, Ice, John A. , Registry, for UK Primary Sjögren's Syndrome, Rischmueller, Maureen , Brun, Johan G. , Gøransson, Lasse G. , Harboe, Erna, Omdal, Roald, Cunninghame‐Graham, Deborah S., Vyse, Tim J., Miceli‐Richard, Corinne , Lessard, James, Wahren‐Herlenius, Marie , Kvarnström, Marika , Illei, Gabor G. , Witte, Torsten, Jonsson, Roland , Nordmark, Gunnel , Ng, Wan‐Fai , Registry, for UK Primary Sjögren's Syndrome, Anaya, Juan‐Manuel , Rhodus, Nelson L., Segal, Barbara, Guthridge, Joel M. , Scofield, R. Hal , Alarcón‐Riquelme, Marta E. , Bae, Sang‐Cheol , Boackle, Susan A., Criswell, Lindsey A. , Gilkeson, Gary S. , Jacob, Chaim O., Kimberly, Robert P. , Brown, Elizabeth E. , Edberg, Jeffrey C., Alarcón, Graciela S. , Reveille, John D. , Vilá, Luis M. , Petri, Michelle , Niewold, Timothy B. , Stevens, Anne M., Tsao, Betty P. , Gorlova, Olga Y. , Wakeland, Ward, Radstake, Timothy R. D. J., Martín, Jose‐Ezequiel , Martı́n, Javier , Siminovitch, Katherine, Sivils, Kathy L., Gaffney, Patrick M. , Langefeld, Carl D. , Harley, John B., Kaufman, Kenneth M. , Niewold, Timothy, Weirauch, Matthew T. , Xie, Gang , Li, He , Nath, Swapan Kumar , Mariette, Xavier , Bowman, Simon , Registry, for UK Primary Sjögren's Syndrome, Lester, Sue , Brennan, Michael Thomas , Eriksson, Per , Registry, for UK Primary Sjögren's Syndrome, Merrill, Joan T. , James, Judith A. , Kamen, Diane L. , Ramsey‐Goldman, Rosalind , Freedman, Barry I. , Ying, Binwu , Mayes, Maureen D. , Hirschfield, Gideon M , Kottyan, Leah C , Guthridge, Joel M

Mayo Clinic

Human Molecular Genetics | September 10, 2014 | Volume: 24 | Issue: 2 | Pages: 582-596

10.1093/hmg/ddu455 | PMID 25205108 Get It

Selective Assembly of DNA-Conjugated Single-Walled Carbon Nanotubes from the Vascular Secretome
Gong, Xun , Sharma, Anil Kumar , Strano, Michael S. , Sharma, Anil K. , Mukhopadhyay, Debabrata , Gong, Xun

Mayo Clinic

ACS Nano | September 3, 2014 | Volume: 8 | Issue: 9 | Pages: 9126-9136

10.1021/nn5026912 | PMID 25184956 Get It

Abstract Colloidal dispersion of single-walled carbon nanotubes (SWCNTs) is often the first processing step to many of their unique applications. However, dispersed SWCNTs often exist in kinetically trapped states where aggregation can be of concern. Recent work revealed prominent DNA–SWCNT aggregation following intravascular injection. In this study, we performed detailed analysis of DNA–SWCNT aggregate formation, structure, and composition in the context of endothelial cell condition media. Interestingly, we found that aggregates formed within condition media from cells that have undergone a stress response differ in size and organization from that of the control. We also found that temperature increases also promote DNA–SWCNT associations. A mathematical model was developed to describe the kinetics of SWCNT extraction from solution. Through orthogonal optical analysis and imaging modalities, we verified that proteins form the bulk of the aggregate structure and dictate aggregate assembly at multiple levels of organization. Finally, physiochemical analysis indicated preferential extraction of low-abundance hydrophobic and charged proteins. The formed aggregates also remain relatively stable in solution, making them potential macroscopic indicators of solution content.
ADHD, Stimulant Treatment, and Growth: A Longitudinal Study
Harstad, Elizabeth , Weaver, Amy L. , Katusic, Slavica K., Colligan, Robert C., Kumar, Seema , Chan, Eugenia, Voigt, Robert G. , Barbaresi, William J.

Mayo Clinic

Pediatrics | September 2, 2014 | Volume: 134 | Issue: 4 | Pages: e935-e944

10.1542/peds.2014-0428 | PMID 25180281 Get It

BACKGROUND AND OBJECTIVE:There is ongoing concern that stimulant medications may adversely affect growth. In a sample of attention-deficit/hyperactivity disorder (ADHD) cases and controls from a population-based birth cohort, we assessed growth and the association between stimulant treatment and growth.METHODS:Subjects included childhood ADHD cases (N = 340) and controls (N = 680) from a 1976 to 1982 birth cohort (N = 5718). Height and stimulant treatment information were abstracted from medical records and obtained during a prospective, adult follow-up study. For each subject, a parametric penalized spline smoothing method modeled height over time, and the corresponding height velocity was calculated as the first derivative. Peak height velocity (PHV) age and magnitude were estimated from the velocity curves. Among stimulant-treated ADHD cases, we analyzed height Z scores at the beginning, at the end, and 24 months after the end of treatment.RESULTS:Neither ADHD itself nor treatment with stimulants was associated with differences in magnitude of PHV or final adult height. Among boys treated with stimulants, there was a positive correlation between duration of stimulant usage before PHV and age at PHV (r = 0.21, P = .01). There was no significant correlation between duration of treatment and change in height Z scores (r = −0.08 for beginning vs end change, r = 0.01 for end vs 24 months later change). Among the 59 ADHD cases treated for ≥3 years, there was a clinically insignificant decrease in mean Z score from beginning (0.48) to end (0.33) of treatment (P = .06).CONCLUSIONS:Our findings suggest that ADHD treatment with stimulant medication is not associated with differences in adult height or significant changes in growth.
Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE)
Sylvia, Louisa G. , Shelton, Richard C. , Kemp, David E. , Bernstein, Emily E. , Friedman, Edward S., Brody, Benjamin D. , Tohen, Mauricio , Bowden, Charles L., Ketter, Terence A. , Deckersbach, Thilo , Thase, Michael E., Reilly-Harrington, Noreen A. , Nierenberg, Andrew A. , Rabideau, Dustin J. , Kinrys, Gustavo , Kocsis, James H., Kamali, Masoud , McInnis, Melvin G. , Calabrese, Joseph R. , McElroy, Susan L. , Singh, Vivek Kumar , Bobo, William V. , Kamali, Masoud , McInnis, Melvin G

Mayo Clinic

Bipolar Disorders | August 16, 2014 | Volume: 17 | Issue: 2 | Pages: 212-223

10.1111/bdi.12243 | PMID 25130321 Get It

ObjectivesIndividuals with bipolar disorder have high rates of other medical comorbidity, which is associated with higher mortality rates and worse course of illness. The present study examined common predictors of medical comorbidity.MethodsThe Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE) enrolled 482 participants with bipolar I or bipolar II disorder in a six‐month, randomized comparative effectiveness trial. Baseline assessments included current and lifetime DSM‐IV‐TR diagnoses, demographic information, psychiatric and medical history, severity of psychiatric symptoms, level of functioning, and a fasting blood draw. Medical comorbidities were categorized into two groups: cardiometabolic (e.g., diabetes, hyperlipidemia, and metabolic syndrome) and non‐cardiovascular (e.g., seizures, asthma, and cancer). Additionally, we looked at comorbid substance use (e.g., smoking and drug dependence).ResultsWe found that 96.3% of participants had at least one other medical comorbidity. Older age predicted a greater likelihood of having a cardiometabolic condition. Early age of onset of bipolar symptoms was associated with a lower chance of having a cardiometabolic condition, but a greater chance of having other types of medical comorbidity. Additional predictors of other medical comorbidities in bipolar disorder included more time spent depressed, less time spent manic/hypomanic, and longer duration of illness. Medications associated with weight gain were associated with low high‐density lipoprotein and abnormal triglycerides.ConclusionsThere appears to be a substantial medical burden associated with bipolar disorder, highlighting the need for collaborative care among psychiatric and general medical providers to address both psychiatric and other medical needs concomitantly in this group of patients.